Marseille-based medtech launches a new generation of painkillers Marseille-based medtech has just been selected by the European Innovation Council for its molecules as alternatives to opioids.

Lire la suite

Tafalgie Therapeutics: an alternative painkiller to opioids Tafalgie Therapeutics is developing a new generation of pain-relieving peptides devoid of the disabling side effects of opioids. This start-up is one of Challenges’ “100 start-ups to invest in in 2024”.

Lire la suite

Tafalgie Therapeutics announces ! We are proud to announce that Tafalgie Therapeutics is one of only a handful of European companies (47 of which 12 are French, out of several thousand applications) to have won the European Innovation Council’s new gas pedal program for its new generation of pain-relieving peptides as an alternative to opioids. […]

Lire la suite

Tafalgie Therapeutics expands R&D capabilities and moves into new premises Tafalgie Therapeutics, a biopharmaceutical research company specialised in the development of treatments capable of relieving and preventing the onset of acute and chronic pain (inflammatory, post-operative, neuropathic) without side effects, announces that its teams are moving today to its new site in Luminy, Marseille, France, […]

Lire la suite

Tafalgie Therapeutics is going to participate in the ‘IPOready’ 2024 program, a pre-IPO program organized by Euronext for the 9th consecutive year Tafalgie Therapeutics, a biopharmaceutical research company specialised in the research and innovation of treatments capable of alleviating and preventing the onset of acute and chronic pain (inflammatory, post-operative, neuropathic) without side effects, is […]

Lire la suite

Aziz Moqrich has been awarded the SATT IMPACT 2022 Prize for his team’s work on the TAFA4 Protein Aziz Moqrich has been awarded the SATT IMPACT 2022 prize for his team’s work on the TAFA4 protein. Dr Moqrich is a Research Director at the IBDM laboratory (part of CNRS, the French Centre National de la […]

Lire la suite
Visit our contact page